PRQR
ProQR Therapeutics BV
1.60$
+0.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +139.7% | +35.5% | +41.7% | -39.0% | +12.1% | +4.9% | -15.5% | -23.6% | +59.3% | -55.5% | +330.9% | – | |
| – | – | – | +2.8% | – | – | – | – | – | – | +4.9% | +1.9% | – | |
| – | +139.7% | +35.5% | +41.7% | -39.0% | +12.1% | +4.9% | -15.5% | -23.6% | +36.2% | -65.7% | +501.4% | – | |
| – | +42.0% | +20.0% | -24.1% | +33.6% | +12.7% | +16.1% | -7.4% | -2.9% | -11.3% | +22.3% | +7.1% | – | |
| – | +43.3% | -27.3% | -12.7% | +9.0% | +19.2% | -17.4% | +48.9% | -35.2% | +24.8% | -1.0% | +27.6% | – | |
| – | +9.0% | +31.1% | -20.9% | +26.8% | +14.6% | +6.6% | +4.8% | -11.6% | -8.4% | +17.1% | +12.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2,520.8% | -99.0% | -9.7% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -87.8% | -40.0% | -6,766.7% | – | – | – | – | – | – | +0.9% | +2,441.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.